Method of preventing retinopathy of prematurity in a neonate

• US 6,344,479 B1
• Filed: 03/20/2001
• Issued: 02/05/2002
• Est. Priority Date: 03/20/2001
• Status: Expired due to Term

• Current Assignee: Farmacon-Il LLC
• Original Assignee: Farmacon-Il LLC
• Inventors: Van Overmeire, Bart, Darko, Laszlo
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US09/813,280
• Time in Patent Office: 322 Days
• Field of Search: 514/555, 514/533, 514/564, 514/534, 514/570, 514/912
• US Class Current: 514/534
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method is disclosed of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation in said neonate.

Claims

1. A method of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation and stimulate normal retinal development and retinal vascularity in said neonate.

2. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is a salt of a basic amino acid.

3. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is ibuprofen lysinate or ibuprofen arginate.

4. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is in the form of the L-isomer.

5. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is in the form of the racemate.

6. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered by intravenous, subcutaneous or intramuscular injection.

7. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered in a daily dosage of 1 to 20 mg based on ibuprofen content.

8. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered in a concentration of 1 to 20 mg/ml in a vehicle acceptable for injection.

9. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered to the prematurely born neonate during the first month of life.

10. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered once a day for 3 days in respective daily doses of about 10 mg, 5 mg and 5 mg per kg of body weight and the administration may be repeated.